Please use this identifier to cite or link to this item:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/82221Full metadata record
| ???org.dspace.app.webui.jsptag.ItemTag.dcfield??? | Value | Language |
|---|---|---|
| dc.contributor.advisor | 李芸湘(Yun-Hsiang Lee) | |
| dc.contributor.author | Chun-Mien Chen | en |
| dc.contributor.author | 陳郡綿 | zh_TW |
| dc.date.accessioned | 2022-11-25T06:33:54Z | - |
| dc.date.copyright | 2022-02-21 | |
| dc.date.issued | 2022 | |
| dc.date.submitted | 2022-01-27 | |
| dc.identifier.citation | 中文部分 大癌照護網（2017）‧篩檢/檢查方法‧引自http://www.crctw.org/crctw_web/QA_ xargs=0 pstart=1 b=11 吳至容、王雅容（2016）．化學治療導致週邊神經病變之探討．腫瘤護理雜誌，16（1），25-33。doi:10.3966/168395442016061601004 林本仁（2019）．大腸直腸癌知多少？．聲洋防癌之聲，（162），24-29。 姚開屏（2002）．健康相關生活品質概念與測量原理之簡介．台灣醫學，6（2），183-192。doi:10.6320/FJM.2002.6（2）.08 姚遠賢、謝東呈、蘇淑芬、王守玉（2011）．現今大腸癌之治療趨勢．弘光學報，（65），72-92。doi:10.6615/HAR.201112.65.06 翁昭旼（2014）．大腸直腸癌的防治．聲洋防癌之聲，（145），7-9。 陳弘益（2015）．大腸癌各分期的藥物治療．藥學雜誌，31（4），68-73。 張簡俊榮（2008）．台灣大腸直腸癌的流行病學．中華民國癌症醫學會雜誌，24（3），143-147。doi:10.6588/JCOS.2008.24.3.1 曹書儀、張育霖、陳進生、黃文威（2017）．腸道微生態失調與大腸直腸癌之關聯．內科學誌，28（3），160-167。doi:10.6314/JIMT.2017.28（3）.06 黃敬倫（2008）．轉移性大腸直腸癌的治療．中華癌醫會誌，24（3），199-202。 曾嘉慶、李嘉龍、吳啓華（2009）．大腸直腸腫瘤的篩檢與追蹤：文獻回顧與最新指引．內科學誌，20（6），506-513。doi:10.6314/JIMT.2009.20（6）.05 衛生福利部國民健康署（2020）‧2017年癌症登記報告‧取自https://www.hpa.gov.tw/Pages/ashx/File.ashx?FilePath=~/File/Attach/12682/File_14670.pdf 劉易承、宋鴻樟、謝玲玲、唐瑞平、葉志清（2008）．大腸直腸癌之風險預測模式與風險指標．台灣公共衛生雜誌，27（1），1-12。doi:10.6288/TJPH2008-27-01-01 鄭淑貞、陳佳琪、張世昌（2018）．大腸直腸癌存活與相關預測因子探討．病歷資訊管理，16（2），50-70。 鄭偉宏、周文其（2014）．轉移性大腸直腸癌藥物治療的進展．台灣醫學，18（6），700-709。doi:10.6320/FJM.2014.18（6）.11 蕭正文（2015）．大腸直腸癌的篩檢．聲洋防癌之聲，(149)，16-19。 謝邦昌、蕭育仁、丁台怡（2019）．癌症與生活型態相關因素之研究．數據分析，14（2），49-68。doi:10.6338/JDA.201904_14（2）.0003 羅淑芬、胡文郁（2008）‧癌症病人健康相關生活品質之概念與測量工具之評析，安寧療護雜誌，13（1），42-57。doi:10.6537/tjhpc.2008.13 英文部分 Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C., Kaasa, S., Klee, M., Osoba, M. D., David, M., Razavi, D., Rofe, P. B., Schraub, S., Sneeuw, K., Sullivan, M., Fumikazu, T. (1993). The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85(5), 365-376. Albers, J. W., Chaudhry, V., Cavaletti, G., Donehower, R. C. (2011). Interventions for preventing neuropathy caused by cisplatin and related compounds. The Cochrane Database of Systematic Reviews, (2), CD005228. doi: 10.1002/14651858.CD005228.pub3 Amin, M. B., Edge, S. B., Greene, F. L., Byrd, D. R., Brookland, R. K., Washington, M. K., Gershenwald, J. E., Compton, C. C., Hess, K. R., Sullivan, D. C., Jessup, J. M., Brierley, J. D., Gaspar, L. E., Schilsky, R. L., Balch, C. M., Winchester, D. P., Asare, E. A., Martin Madera, M., Gress, D. M., Meyer, L. R. (2017). American Joint Committee on Cancer Staging Manual, 8th Edition. Springer Bandla, A., Sundar, R., Liao, L. D., Sze Hui Tan, S., Lee, S. C., Thakor, N. V., Wilder-Smith, E. P. (2016). Hypothermia for preventing chemotherapy-induced neuropathy - a pilot study on safety and tolerability in healthy controls. Acta Oncologica, 55(4), 430-436. doi:10.3109/0284186X.2015.1075664 Cappell, M. S. (2008). Pathophysiology, Clinical Presentation, and Management of Colon Cancer. Gastroenterology Clinics of North America, 37(1), 1-24. doi:10.1016/j.gtc.2007.12.002 Cathomas, R., Köberle, D., Ruhstaller, T., Mayer, G., Räss, A., Mey, U., von Moos, R. (2009). Heated (37°C) oxaliplatin infusion in combination with capecitabine for metastatic colorectal carcinoma: can it reduce neuropathy? Supportive Care in Cancer, 18(10), 1263-1270. doi:10.1007/s00520-009-0740-1 Cavaletti, G., Frigeni, B., Lanzani, F., Mattavelli, L., Susani, E., Alberti, P., Cortinovis, D., Bidoli, P. (2010). Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools. European Journal of Cancer, 46(3), 479-494. doi:10.1016/j.ejca.2009.12.008 Cavaletti, G., Frigeni, B., Lanzani, F., Piatti, M., Rota, S., Briani, C., Zara, G., Plasmati, R., Pastorelli, F., Caraceni, A., Pace, A., Manicone, M., Lissoni, A., Colombo, N., Bianchi, G., Zanna, C.(2010). The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale. Journal of the Peripheral Nervous System, 12(3):210-5 Chiang TH, Lee YC, Tu CH, Chiu HM, Wu MS. (2011). Performance of the immunochemical fecal occult blood test in predicting lesions in the lower gastrointestinal tract. The Canadian Medical Association Journal, 183(13):1474-81 Clark, J., Grothey, A. (2019). Systemic chemotherapy for metastatic colorectal cancer: General principles. In D. M. Savarese (Ed), UpToDate. Retrieved October 21, 2019, from https://www.uptodate.com/contents/systemic-chemotherapy-for-metastatic-colorectal-cancer-general-principles?search=colorectal-cancer-treatment source=search_result selectedTitle=4~150 usage_type=default display_rank=4 Derksen, T.M.E., Bours, M.J.L., Mols, F., Weijenberg, M.P. (2017).Lifestyle-related factors in the self-management of chemotherapy-induced peripheral neuropathy in colorectal cancer: A systematic review. Evidence-Based Complementary and Alternation Medicine, 2017, 1-14 De Lemos ML, Walisser S. (2005). Management of extravasation of oxaliplatin. Journal of Oncology Pharmacy Practice, 11(4):159-62 Drott, J., Fomichov, V., Starkhammar, H., Borjeson, S., Kjellgren, K., Bertero, C. (2019). Oxaliplatin-Induced Neurotoxic Side Effects and Their Impact on Daily Activities: A Longitudinal Study Among Patients With Colorectal Cancer. Cancer Nursing, 42(6), 40-48. https://doi.org/10.1097/NCC.0000000000000674 Scott, N., Fayers, P., Aaronson, N., Bottomley, A., de Graeff, A., Groenvold, M., Gundy, C., Koller, M., Sprangers, M. A. G. (2001). EORTC QLQ-C30 Scoring Manual (3rd edition). Brussels: EORTC. Fehrenbacher, J. C. (2015). Chemotherapy-induced peripheral neuropathy. Progress in Molecular Biology and Translational Science, 131, 471-508. doi:10.1016/bs.pmbts.2014.12.002 Ferrell, B., Dow, K. H. (1997). Quality of Life among Long-Term Cancer Survivors. Oncology, 11(4), 565-571. Flatters, S. J. L., Dougherty, P. M., Colvin, L. A. (2017). Clinical and preclinical perspectives on Chemotherapy-Induced Peripheral Neuropathy (CIPN): a narrative review. British Journal of Anaesthesia, 119(4), 737-749. doi:10.1093/bja/aex229 Gomez, D., Calderon, C., Carmona-Bayonas, A., Cacho Lavin, D., Munoz, M. M., Martinez Cabanez, R., Jimenez-Fonseca, P. (2021). Impact of adjuvant therapy toxicity on quality of life and emotional symptoms in patients with colon cancer: a latent class analysis. Clinical and Translational Oncology, 23(3), 657-662. https://doi.org/10.1007/s12094-020-02454-z Gujral, S., Conroy, T., Fleissner, C., Sezer, O., King, P. M., Avery, K. N. L., . . . Blazeby, J. M. (2007). Assessing quality of life in patients with colorectal cancer: An update of the EORTC quality of life questionnaire. European Journal of Cancer, 43(10), 1564-1573. doi:10.1016/j.ejca.2007.04.005 Hanai, A., Ishiguro, H., Sozu, T., Tsuda, M., Yano, I., Nakagawa, T., Imai, S., Hamabe, Y., Toi, M., Arai, H., Tsuboyama, T. (2018). Effects of Cryotherapy on Objective and Subjective Symptoms of Paclitaxel-Induced Neuropathy: Prospective Self-Controlled Trial. Journal of the National Cancer Institute, 110(2), 141-148. doi:10.1093/jnci/djx178 Hausheer, F. H., Schilsky, R. L., Bain, S., Berghorn, E. J., Lieberman, F. (2006). Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Seminars in Oncology, 33(1), 15-49. doi:10.1053/j.seminoncol.2005.12.010 Horton, N. J., Lipsitz, S. R. (1999). Review of software to fit generalized estimating equation regression models. The American Statistician, 53, 160-169. Kang, L., Tian, Y., Xu, S., Chen, H. (2020). Oxaliplatin-induced peripheral neuropathy: Clinical features, mechanisms, prevention and treatment. Journal of Neurology, 268(9), 3269-3282. https://doi.org/10.1007/s00415-020-09942-w Kung-Yee Liang, Scott L. Zeger. (1986). Longitudinal data analysis using generalized linear models. Biometrika, 73(1), 13–22. https://doi.org/10.1093/biomet/73.1.13 Macrae, F., Bendell, J. (2019). Clinical presentation, diagnosis, and staging of colorectal cancer. In D. M. Savarese (Ed.), UpToDate. Retrieved October 21, 2019, from https://www.uptodate.com/contents/clinical-presentation-diagnosis-and-staging-of-colorectal-cancer Mamon , H., Enzinger , P. (2021). Adjuvant and neoadjuvant treatment of gastric cancer. UpToDate. Retrieved October 20, 2021, from https://www.uptodate.com/contents/adjuvant-and-neoadjuvant-treatment-of-gastric-cancer?search=Stomach%20Cancer source=search_result selectedTitle=2~150 usage_type=default display_rank=2 Mansfield, P., (2021). Clinical features, diagnosis, and staging of gastric cancer. UpToDate. Retrieved December 13, 2021, from https://www.uptodate.com/contents/clinical-features-diagnosis-and-staging-of-gastric-cancer?search=Stomach%20Cancer source=search_result selectedTitle=1~150 usage_type=default display_rank=1 Mols, F., Beijers, A. J., Vreugdenhil, G., Verhulst, A., Schep, G., Husson, O. (2015). Chemotherapy-induced peripheral neuropathy, physical activity and health-related quality of life among colorectal cancer survivors from the PROFILES registry. Journal of Cancer Survivorship, 9(3), 512-522. doi:10.1007/s11764-015-0427-1 Mols, F., Beijers, T., Lemmens, V., van den Hurk, C. J., Vreugdenhil, G., van de Poll-Franse, L. V. (2013). Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry. Journal of Clinical Oncology, 31(21), 2699-2707. doi:10.1200/JCO.2013.49.1514 Mols, F., Beijers, T., Vreugdenhil, G., van de Poll-Franse, L. (2014). Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review. Support Care Cancer, 22(8), 2261-2269. doi:10.1007/s00520-014-2255-7 National Cancer Institute Cancer.(2017), Common Terminology Criteria for Adverse Events Version 5.0, Retrieved from https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf Park, R., Park, C. (2015). Comparison of Foot Bathing and Foot Massage in Chemotherapy-Induced Peripheral Neuropathy. Cancer Nursing, 38(3), 239-247. doi:10.1097/NCC.0000000000000181 Park, S. B., Goldstein, D., Krishnan, A. V., Lin, C. S., Friedlander, M. L., Cassidy, J., Koltzenburg, M., Kiernan, M. C. (2013) Chemotherapy-induced peripheral neurotoxicity: a critical analysis. A Cancer Journal for Clinicians, 63(6):419-37 Postma, T. J., Aaronson, N. K., Heimans, J. J., Muller, M. J., Hildebrand, J. G., Delattre, J. Y., Hoang-Xuan, K., Lantéri-Minet, M., Grant, R., Huddart, R., Moynihan, C., Maher, J., Lucey, R., EORTC Quality of Life Group (2005). The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. European Journal of Cancer, 41(8), 1135-1139. doi: 10.1016/j.ejca.2005.02.012 Prendergast, J. J., Miranda, G., Sanchez, M. (2004). Improvement of sensory impairment in patients with peripheral neuropathy. Endocrine Practice, 10(1), 24–30. doi:10.4158/ep.10.1.24 Schwartz CE, Sprangers MA. (2002). An introduction to quality of life assessment in oncology: the value of measuring patient-reported outcomes. American Journal of Managed Care. 8(18).550-559 Sexton, R. E., Al Hallak, M. N., Diab, M., Azmi, A. S. (2020). Gastric cancer: a comprehensive review of current and future treatment strategies. Cancer and Metastasis Reviews, 39(4), 1179-1203. https://doi.org/10.1007/s10555-020-09925-3 Shen, M.H., Chen, L.P., Ho, T.F., Shih, Y.Y., Huang, C.S., Chie, W.C., Huang, C.C. (2018). Validation of the Taiwan Chinese version of the EORTC QLQ-CR29 to assess quality of life in colorectal cancer patients. BMC Cancer, 18(1). doi:10.1186/s12885-018-4312-y Shih, W. (1997). Sample Size and Power Calculations for Periodontal and Other Studies with Clustered Samples Using the Method of Generalized Estimating Equations. Biometrical Journal Biometrische Zeitschrift ., 39(8), 899–908. https://doi.org/10.1002/bimj.4710390803 Soveri, L. M., Lamminmaki, A., Hanninen, U. A., Karhunen, M., Bono, P., Osterlund, P. (2019). Long-term neuropathy and quality of life in colorectal cancer patients treated with oxaliplatin containing adjuvant chemotherapy. Acta Oncologica, 58(4), 398-406. doi:10.1080/0284186X.2018.1556804 Sun, P. C., Kuo, C. D., Chi, L. Y., Lin, H. D., Wei, S. H., Chen, C. S. (2013). Microcirculatory vasomotor changes are associated with severity of peripheral neuropathy in patients with type 2 diabetes. Diabetes and Vascular Disease Research, 10(3), 270-276. doi:10.1177/1479164112465443 Tanay, M. A. L., Armes, J., Ream, E. (2016). The experience of chemotherapy-induced peripheral neuropathy in adult cancer patients: a qualitative thematic synthesis. European Journal of Cancer Care, 26(5). https://doi.org/10.1111/ecc.12443 Teng, C., Cohen, J., Egger, S., Blinman, P. L., Vardy, J. L. (2022). Systematic review of long-term chemotherapy-induced peripheral neuropathy (CIPN) following adjuvant oxaliplatin for colorectal cancer. Support Care Cancer, 30(1), 33-47. https://doi.org/10.1007/s00520-021-06502-4 Tofthagen, C., Donovan, K.A., Morgan, M.A., Shibata, D., Yeh, Y. (2013). Oxaliplatin-induced peripheral neuropathy’s effects on health-related quality of life of colorectal cancer survivors. Support Care Cancer, 21, 3307-3313. doi:10.1007/s00520-013-1905-5 Visovsky, C., Collins, M., Abbott, L., Aschenbrenner, J., Hart. C. (2007). Putting evidence into practice: Evidence-based interventions for chemotherapy-induced peripheral neuropathy. Clinical Journal of Oncology Nursing, 11(6), 901-913. Wan, C., Meng, Q., Yang, Z., Tu, X., Feng, C., Tang, X., Zhang, C. (2008). Validation of the simplified Chinese version of EORTC QLQ-C30 from the measurements of five types of inpatients with cancer. Annals of Oncology, 19(12), 2053-2060. doi:10.1093/annonc/mdn417 World Health Organization. International Agency for Research on Cancer. (2020). World Cancer Report. cancer research for cancer prevention. https://www.iccp-portal.org/system/files/resources/IARC%20World%20Cancer%20Report%202020.pdf. World Health Organization. Division of Mental Health and Prevention of Substance Abuse. (1997). WHOQOL : measuring quality of life. World Health Organization. https://apps.who.int/iris/handle/10665/63482 Yan H, Sellick K. (2004). Symptoms, psychological distress, social support, and quality of life of Chinese patients newly diagnosed with gastrointestinal cancer. Cancer Nursing.27(5):389-99 Zajączkowska, R., Kocot-Kępska, M., Leppert, W., Wrzosek, A., Mika, J., Wordliczek, J. (2019). Mechanisms of Chemotherapy-Induced Peripheral Neuropathy. International Journal of Molecular Sciences, 20(6). doi:10.3390/ijms20061451 Zebrack, B. J., Yi, J., Petersen, L., Ganz, P. A. (2008). The impact of cancer and quality of life for long-term survivors. Psychooncology, 17(9), 891-900. doi:10.1002/pon.1300 | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/82221 | - |
| dc.description.abstract | "研究背景：胃癌與大腸癌病人於臨床上使用Oxaliplatin及5-FU作為化療藥物，以提高反應率及延長整體存活期，但也面臨不良反應如Oxaliplatin最著名的副作用-化學治療引起周邊神經病變（chemotherapy-induced peripheral neuropathy, CIPN），此副作用嚴重時需減少化療劑量及停止治療，影響癌症控制、存活及生活品質，目前CIPN尚無早期介入相關研究，本研究將針對此議題進行研究。 研究目的：探討熱敷護理方案早期介入對大腸癌、胃癌病人接受Oxaliplatin造成周邊神經病變與生活品質之成效。 研究方法：本研究採隨機分配之類實驗性研究設計，自2020年7月1日至2021年8月31日，以台北市某醫學中心腫瘤門診診斷為大腸癌或胃癌術後且初次以Oxaliplatin作為化療藥物之病人作為收案對象。實驗組：使用恆熱熱療法於手掌及腳掌；控制組：採臨床化療常規照護。兩組於治療前（T0, 基準值）、與治療後第2（T1）、4（T2）、6（T3）、8（T4）、10（T5）及12（T6）週進行周邊神經病變程度之EORTC QLQ-CIPN20測量，以及於治療後第4（T2）、8（T4）及12（T6）進行周邊神經病變程度之NCI-CTCAE V5.0及生活品質EORTC-QLQ-C30的測量，最後以廣義推估模式（GEE）分析確認兩組成效之差異。 研究結果：熱敷護理方案介入的CIPN嚴重度於EORTC QLQ-CIPN20量表中感覺神經分辨熱水及冷水困難具有顯著改善（p=0.04）；在運動神經精細動作上握筆寫字（p=0.05）和手打開罐子的力氣（p= 0.01）也具有顯著的改善，於生活品質（EORTC-QLQ-C30）沒有顯著差異，但整體健康/生活品質、整體功能及症狀問題等次量表熱敷組都比控制組狀況佳的趨勢。 結論：熱敷護理方案介入能改善周邊感覺神經的溫度感覺及運動神經的精細動作;建議將熱敷護理方案納入接受oxaliplatin治療之大腸癌及胃癌病人常規的護理措施內容，以改善其周邊神經病變之不適症狀，進而提升生活品質。" | zh_TW |
| dc.description.provenance | Made available in DSpace on 2022-11-25T06:33:54Z (GMT). No. of bitstreams: 1 U0001-2101202210405100.pdf: 6340559 bytes, checksum: e0f0a47941d56c69ca613d2e9c90aff3 (MD5) Previous issue date: 2022 | en |
| dc.description.tableofcontents | "目錄 口試委員會審定書...........................................................i 中文摘要.................................................................ii 英文摘要................................................................iii 目錄....................................................................v 圖目錄.................................................................vii 表目錄................................................................viii 第一章 緒論..............................................................1 第一節 研究背景、動機及重要性 ..............................................1 第二節 研究目的...........................................................3 第二章 文獻查證...........................................................4 第一節 大腸癌及胃癌的診斷及治療..............................................4 第二節 化學治療造成周邊神經病變的機轉與相關因素................................9 第三節 周邊神經病變對生活品質的影響..........................................15 第四節 化學治療引起周邊神經病變之冷熱相關介入措施...............................18 第三章 研究方法............................................................24 第一節 研究設計............................................................24 第二節 研究架構............................................................26 第三節 研究場所與對象.......................................................27 第四節 研究問題與假設.......................................................28 第五節 名詞解釋及操作型定義..................................................29 第六節 研究工具............................................................30 第七節 研究步驟............................................................33 第八節 介入措施............................................................35 第九節 資料處理與分析統計....................................................36 第十節 研究倫理考量..........................................................37 第四章 研究結果.............................................................38 第一節 研究對象之收案與追蹤...................................................38 第二節 研究個案基本資料及前測結果..............................................39 第三節 熱敷護理介入前、後於化療相關周邊神經病變程度之變化與成效…....................43 第四節 熱敷護理方案介入前、後於生活品質之變化與成效...............................55 第五章 討論.................................................................58 第一節 CIPN症狀嚴重度及趨勢變化之成效...........................................58 第二節 生活品質影響與趨勢變化之成效..............................................60 第六章 結論與建議.............................................................61 第一節 結論..................................................................61 第二節 建議與限制.............................................................64 參考文獻…....................................................................65 圖目錄 圖2.2.1 CIPN致病機轉…........................................................11 圖3.2.1 研究架構………..........................................................26 圖3.6.1 博依熱敷墊（Beurer HK 44 Heat Pad）...................................32 圖3.6.2 博依暖暖護腳套（Beurer FW 20 Cosy foot warmer）........................32 圖3.7.1 研究步驟流程圖........................................................34 圖4.1.1 收案與追蹤流程圖......................................................38 圖4.3.1 兩組周邊神經病（EORTC QLQ-CIPN20）子題之比較............................47 圖4.3.2 兩組周邊神經病（EORTC QLQ-CIPN20）量表之比較............................51 圖4.3.3 NCI-CTCAE Version 5.0周邊感覺及運動神經病變發生率.......................54 圖4.4.1 兩組生活品質（EORTC-QLQ-C30）之比較……….................................57 表目錄 表2.1.1 大腸癌TNM分期系統第八版（Tumor node metastasis, TNM）...................6 表2.1.2 胃癌TNM分期系統第八版（Tumor node metastasis, TNM）.....................7 表2.4.1 熱敷與周邊神經病變相關研究整理...........................................21 表3.1.1 研究資料收集流程.......................................................25 表4.2.1 研究個案基本資料.......................................................39 表4.2.2 疾病屬性及醫療特性.....................................................40 表4.2.3 兩組化療相關周邊神經病變程度EORTC QLQ-CIPN20前測結果......................42 表4.2.4 兩組生活品質EORTC-QLQ-C30量表前測結果...................................42 表4.3.1 熱敷護理介入對兩組周邊神經病（EORTC QLQ-CIPN20）子題影響…..................44 表4.3.2 熱敷護理方案介入對兩組周邊神經病（EORTC QLQ-CIPN20）影響…..................47 表4.3.3 兩組周邊神經病（EORTC QLQ-CIPN20）量表之平均值與標準差 ……..................52 表4.3.4 熱敷護理介入對兩組NCI-CTCAE V 5.0感覺及運動神經病變之影響….................53 表4.3.5 NCI-CTCAE Version 5.0周邊感覺及運動神經病變發生率........................54 表4.4.1 熱敷護理方案介入對兩組生活品質（EORTC-QLQ-C30）之影響………...................56 表4.4.2 兩組生活品質（EORTC-QLQ-C30）之平均值與標準差………………….....................56" | |
| dc.language.iso | zh-TW | |
| dc.subject | 胃癌 | zh_TW |
| dc.subject | 大腸癌 | zh_TW |
| dc.subject | 化學治療 | zh_TW |
| dc.subject | 熱敷 | zh_TW |
| dc.subject | 周邊神經病變 | zh_TW |
| dc.subject | 生活品質 | zh_TW |
| dc.subject | Colon cancer | en |
| dc.subject | chemotherapy | en |
| dc.subject | hot compressing | en |
| dc.subject | chemotherapy-induced peripheral neuropathy | en |
| dc.subject | quality of life | en |
| dc.subject | Gastric cancer | en |
| dc.title | 熱敷護理方案介入大腸癌與胃癌病人化學治療期間周邊神經病變與生活品質之成效 | zh_TW |
| dc.title | The Effects of Hot Compression Intervention for Colon and Gastric Cancer Patients in Chemotherapy-Induced Peripheral Neuropathy and Quality of Life | en |
| dc.date.schoolyear | 110-1 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 賴裕和(Chen-Fen Huang),梁逸歆(Mao-Hsiung Chiang),(Sheng-Wei Huang),(Wei-Kuo Yen) | |
| dc.subject.keyword | 大腸癌,胃癌,化學治療,熱敷,周邊神經病變,生活品質, | zh_TW |
| dc.subject.keyword | Colon cancer,Gastric cancer,chemotherapy,hot compressing,chemotherapy-induced peripheral neuropathy,quality of life, | en |
| dc.relation.page | 74 | |
| dc.identifier.doi | 10.6342/NTU202200137 | |
| dc.rights.note | 未授權 | |
| dc.date.accepted | 2022-01-27 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 護理學研究所 | zh_TW |
| dc.date.embargo-lift | 2027-01-27 | - |
| Appears in Collections: | 護理學系所 | |
Files in This Item:
| File | Size | Format | |
|---|---|---|---|
| U0001-2101202210405100.pdf Restricted Access | 6.19 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.